Vadlīniju pilns teksts

17. Genest DR, Partial Hydatidiform Mole: Clinicopathological Features, Differential
Diagnosis, Ploidy and Molecular Studies and Gold Standards for Diagnosis. Int.J. Ginecol.
Path., 20: 315 – 322, 2001.
18. Cole LA, Khanlian SA, Muller CY, Giddings A, Kohorn EI, Berkowitz R.
Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free beta-subunit, a
reliable marker of placental site trophoblastic tumours. Gynecol Oncol. 2006;102:160-4.
19. Newlands ES, Bagshawe KD, Begent RHJ, Rustin GJS, Holden L: Results with the
EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine)
regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br. J. Obstet.
Gynaecol. 98:550-7, 1991.
20. Kohorn EI: Decision Making for Chemotherapy Administration in Patients with
Low-Risk Gestational Trophoblastic Neoplasia. Int. J. Gynecol Cancer.6:279 -285, 1996.
21. Rustin GJS, Newlands ES, Begent RHJ, Dent J, Bagshawe KD: Weekly
Alternating Etoposide, Methotrexate, and Actinomycin/Vincristine and Cyclophosphamide
Chemotherapy for the Treatment of CNS Metastases of Choriocarcinoma. J. Clin. Oncol.
7:900-903, 1989.
22. Kohorn EI; Is lack of response to Single-Agent Chemotherapy in Gestational
Trophoblastic Disease Associate with Dose Scheduling or Chemotherapy Resistance?
Gynecol. Oncol. 85: 36-39, 2002.
110